Global Peptide Therapeutics Market 2020-2026: Focus on Cancer, Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, and Others – ResearchAndMarkets.com
November 18, 2020DUBLIN–(BUSINESS WIRE)–The “Peptide Therapeutics Market 2020-2026” report has been added to ResearchAndMarkets.com’s offering.
The global peptide therapeutics market is projected to grow at a significant CAGR during the forecast period.
The key factors that drive the growth of the market include the increased incidences of several disorders such as cancer, gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others; along with the availability and development of advanced drugs for the treatment.
Further, the growth of the market is also associated with the increased investments in the R&D for the drug discovery and presence of strong product pipeline in the market. Further, the increased clinical trials in the market also drives the global peptide therapeutics market during the forecast period.
The global peptide therapeutics market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into oral and parenteral. Based on the application, the market is segmented into cancer, gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others. Peptide therapeutics for cancer tend to contribute a considerable share to the market growth. Respiratory disorders segment is projected to exhibit considerable growth rate during the forecast period.
North America is estimated to contribute a significant share in the market. While Asia-Pacific is estimated to exhibit a considerable growth rate during the forecast period.
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Amgen Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Eli Lilly and Co.
3.1.3. Pfizer Inc.
3.1.4. Bristol-Myers Squibb Co.
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Peptide Therapeutics Market by Route of Administration
5.1.1. Oral
5.1.2. Parenteral
5.2. Global Peptide Therapeutics Market by Application
5.2.1. Cancer
5.2.2. Gastrointestinal Disorders
5.2.3. Central Nervous System Disorders
5.2.4. Respiratory Disorders
5.2.5. Others
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Amgen, Inc.
7.2. AstraZeneca Plc
7.3. Bachem Holding AG
7.4. Bristol-Myers Squibb Co.
7.5. CordenPharma InternationalGmbH
7.6. Eli Lilly and Co.
7.7. F. Hoffmann-La Roche Ltd.
7.8. GlaxoSmithKline Plc
7.9. Lonza Group AG
7.10. Merck & Co. Inc.
7.11. Novartis International AG
7.12. Novo Nordisk A/S
7.13. Pfizer, Inc.
7.14. PolyPeptide Group
7.15. Sanofi SA
7.16. Takeda Pharmaceutical Co. Ltd.
7.17. Teva Pharmaceuticals Industries Ltd.
7.18. Xenetic Biosciences, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/hll1f0
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900